Trial Profile
A retrospective case series evaluating safety and efficacy of Nivolumab for treatment of recurrent glioblastoma (GBM) progressed on Bevacizumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 09 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology